NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC)
Clinical trials for NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC) explained in plain language.
Never miss a new study
Get alerted when new NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC) trials appear
Sign up with your email to follow new studies for NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Matched conditions: NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New drug KO-2806 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called KO-2806 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer medicines. The main goals are to check safety and see if the drug can shrink tumors.
Matched conditions: NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC